Invictus appoints Blaney to advisory board

2015-02-02 08:35 ET - News Release



Mr. Dan Kriznic reports
INVICTUS MD STRATEGIES APPOINTS DR. GREG BLANEY TO ADVISORY BOARD
Invictus MD Strategies Corp. has appointed Dr. Greg Blaney, MD, to the company's advisory board. Dr. Blaney has been practising holistic medicine for over 30 years, dedicated to helping people negotiate the limitations of institutionalized medicine at the start of his career. Bridging the more traditional scientific approach with naturopathic protocols, he specializes in a wide range of modalities. As a medical student (University of Ottawa) he was part of a study program established to investigate cannabis and its effects on performance and cognitive abilities. Dr. Blaney has been presented at numerous International Congresses and is now recognized internationally for his expertise in the underlying conditions that perpetuate chronic disease.

In 1983 he began his training in manual medicine at the College of Osteopathic Medicine, Michigan State University. At present, he is involved with the University of British Columbia in the investigation of chronic illness. He is recognized by the government of Canada through the scientific research and economic development program, and is author to scientific papers published in peer-reviewed journals. Dr. Blaney has co-developed several community-based wellness programs and facilitated numerous workshops and intensive retreats throughout North America and Europe. Dan Kriznic, president and chief executive officer, commented: "Dr. Blaney will be assisting Invictus MD with medicinal cannabis research and development and will be instrumental to launching the company's patient management system under the brand VitaLeaf. On behalf of the team at Invictus MD, we are excited to work with such an influential medical doctor with years of experience and innovation related to chronic illness. We want to welcome Dr. Blaney to the team and look forward to our future successes."

Pursuant to the appointment, the company has granted 300,000 incentive stock options exercisable at 15 cents for a period of five years from the date of grant, subject to regulatory approval.